drugset / Trial / NCT00392288

Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.

NCT00392288

Phase 3 Completed 528 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

Primary objective: To demonstrate the efficacy of ciclesonide, compared to placebo, at 80 μg twice daily (BID) or 40 μg BID for 12 weeks in patients with persistent asthma. Secondary objective: To assess the safety and tolerability of ciclesonide.

Timeline

Start
2006-09
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciclesonide Other / unclassified 40 ug Inhaled
Subject Ciclesonide Other / unclassified 80 ug Inhaled

Indications